 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...494495496497498499500501502503504...507508» |
- RG7112 / Roche
Enrollment change, Combination therapy: A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 24, 2013
P1, N=23, Completed, Sponsor: Hoffmann-La Roche
N=36 --> 23
- ||| melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment open: Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=138, Recruiting, Sponsor: Children's Oncology Group
N=36 --> 23 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment open, Surgery: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov) - Jun 19, 2013
P2, N=48, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- doxorubicin hydrochloride / Generic mfg.
New P2 trial: Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer (clinicaltrials.gov) - Jun 18, 2013
P2, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Trial termination, BRCA Biomarker, Surgery, Metastases: Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Jun 17, 2013
P2, N=16, Terminated, Sponsor: National Cancer Centre, Singapore
Not yet recruiting --> Recruiting Recruiting --> Terminated
- ||||| dactinomycin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial initiation date, Surgery: Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor (clinicaltrials.gov) - Jun 17, 2013
P3, N=808, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Terminated Initiation date: Jun 2006 --> Oct 2006
- Enrollment change, BRCA Biomarker, Surgery, Metastases: Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Jun 17, 2013
P2, N=16, Terminated, Sponsor: National Cancer Centre, Singapore
Initiation date: Jun 2006 --> Oct 2006 N=72 --> 16
- ||||| Marqibo (vincristine liposomal) / Servier, Aurobindo
Enrollment closed, Metastases: AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov) - Jun 17, 2013
P3, N=395, Active, not recruiting, Sponsor: Children's Oncology Group
N=72 --> 16 Recruiting --> Active, not recruiting
- Herceptin (trastuzumab) / Roche
Trial completion, Metastases: Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer (clinicaltrials.gov) - Jun 16, 2013
P2, N=85, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| cisplatin / Generic mfg.
Enrollment closed, Surgery: Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor (clinicaltrials.gov) - Jun 13, 2013
P3, N=78, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, IO biomarker, Metastases: Phase II Bevacizumab + Tax In Advanced Breast Cancer (clinicaltrials.gov) - Jun 13, 2013
P2, N=49, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change, Surgery: EURAMOS-1: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Jun 11, 2013
P3, N=1164, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=2300 --> 1164
- Herceptin (trastuzumab) / Roche
Enrollment change, Adverse events: Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=200, Recruiting, Sponsor: Vanderbilt University
N=2300 --> 1164 N=40 --> 200
- | prednisone / Generic mfg.
Trial completion: Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 10, 2013
P3, N=392, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=40 --> 200 Active, not recruiting --> Completed
- ||||| Enrollment change: Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 9, 2013
P3, N=287, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=400 --> 287
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (clinicaltrials.gov) - Jun 9, 2013
P1/2, N=51, Recruiting, Sponsor: National Cancer Institute (NCI)
N=400 --> 287 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Trial initiation date: Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov) - Jun 6, 2013
P2, N=155, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Initiation date: Feb 2013 --> Jun 2013
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Enrollment open: Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov) - Jun 6, 2013
P2, N=155, Recruiting, Sponsor: St. Jude Children's Research Hospital
Initiation date: Feb 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Roche
New P2 trial, Surgery: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov) - Jun 5, 2013
P2, N=48, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment closed, Combination therapy, Metastases: A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies (clinicaltrials.gov) - Jun 5, 2013
P1/2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- zoledronic acid / Generic mfg.
Enrollment change, Metastases: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=24, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting N=30 --> 24
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment change, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Jun 3, 2013
P2, N=42, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=30 --> 24 N=110 --> 42
- bortezomib / Generic mfg., cyclophosphamide / Generic mfg.
New P4 trial, Combination therapy: A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2013
P4, N=50, Recruiting, Sponsor: Peking University People's Hospital
- humanised dinutuximab (Hu14.18K322A) / Renaissance Pharma
Enrollment open, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Jun 3, 2013
P2, N=42, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=110 --> 42 Not yet recruiting --> Recruiting
- ||||||| Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion, Metastases: T-Cell #4: Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 3, 2013
P3, N=573, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change: Healing Touch During Chemotherapy Infusions for Women With Breast Cancer (clinicaltrials.gov) - Jun 2, 2013
P=N/A, N=32, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed N=45 --> 32
- Adcetris (brentuximab vedotin) / Seagen, Takeda
Clinical: Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov) - Jun 2, 2013
P=N/A, N=30, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Trial completion: Healing Touch During Chemotherapy Infusions for Women With Breast Cancer (clinicaltrials.gov) - Jun 2, 2013
P=N/A, N=32, Completed, Sponsor: Stanford University
N=45 --> 32 Active, not recruiting --> Completed
- || lenalidomide / Generic mfg.
New P3 trial: MCL R2: R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL (clinicaltrials.gov) - May 28, 2013
P3, N=633, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
- doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - May 28, 2013
P2, N=0, Completed, Sponsor: Hackensack University Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Enrollment change: ALL-BFM-2000: Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 27, 2013
P3, N=4559, Completed, Sponsor: University of Schleswig-Holstein
Active, not recruiting --> Completed N=2000 --> 4559
- | temozolomide / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Combination therapy: Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - May 27, 2013
P2, N=83, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Biomarker, Trial completion: S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil (clinicaltrials.gov) - May 27, 2013
P=N/A, N=750, Completed, Sponsor: Southwest Oncology Group
N=2000 --> 4559 Recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: ALL-BFM-2000: Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 27, 2013
P3, N=4559, Completed, Sponsor: University of Schleswig-Holstein
Recruiting --> Completed Recruiting --> Completed
- | Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 22, 2013
P2, N=120, Recruiting, Sponsor: Hannover Medical School
- ||||| thioguanine / Generic mfg.
Enrollment change: AALL0331: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 21, 2013
P3, N=5377, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed N=3381 --> 5377
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 21, 2013
P3, N=397, Completed, Sponsor: Southwest Oncology Group
N=3381 --> 5377 Recruiting --> Completed
- Trial withdrawal: Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer (clinicaltrials.gov) - May 20, 2013
P2, N=0, Withdrawn, Sponsor: University of Southern California
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer (clinicaltrials.gov) - May 20, 2013
P2, N=0, Withdrawn, Sponsor: University of Southern California
Not yet recruiting --> Withdrawn N=124 --> 0
- | melphalan / Generic mfg.
Enrollment change: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
N=124 --> 0 N=500 --> 899
- | melphalan / Generic mfg.
Trial completion: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
N=500 --> 899 Active, not recruiting --> Completed
- Biomarker, New P2 trial: Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (clinicaltrials.gov) - May 19, 2013
P2, N=40, Recruiting, Sponsor: Baylor College of Medicine
- | doxorubicin hydrochloride / Generic mfg.
New P2 trial, Monotherapy: Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient (clinicaltrials.gov) - May 19, 2013
P2, N=60, Recruiting, Sponsor: Shi-Ming Lin
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed: Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers (clinicaltrials.gov) - May 19, 2013
P=N/A, N=550, Active, not recruiting, Sponsor: University of South Florida
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
New P2 trial, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - May 16, 2013
P2, N=42, Recruiting, Sponsor: St. Jude Children's Research Hospital
- | Rituxan (rituximab) / Roche
New P2 trial: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - May 15, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Metastases: Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov) - May 15, 2013
P2, N=120, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- thalidomide / Generic mfg.
Trial termination: Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall (clinicaltrials.gov) - May 14, 2013
P2, N=23, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated
- thalidomide / Generic mfg.
Enrollment change: Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall (clinicaltrials.gov) - May 14, 2013
P2, N=23, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated N=44 --> 23
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial, Combination therapy: PHOENIX: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 14, 2013
P3, N=800, Recruiting, Sponsor: Janssen Research & Development, LLC